+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Systemic Lupus Erythematosus (Sle) Drugs - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5140542
Global Systemic Lupus Erythematosus (Sle) Drugs Market to Reach $264.5 Million by 2027

Amid the COVID-19 crisis, the global market for Systemic Lupus Erythematosus (Sle) Drugs estimated at US$183.3 Million in the year 2020, is projected to reach a revised size of US$264.5 Million by 2027, growing at a CAGR of 5.4% over the period 2020-2027.





The U.S. Market is Estimated at $54 Million, While China is Forecast to Grow at 5% CAGR

The Systemic Lupus Erythematosus (Sle) Drugs market in the U.S. is estimated at US$54 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$46.6 Million by the year 2027 trailing a CAGR of 5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Select Competitors (Total 43 Featured):
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Immunomedics, Inc.
  • Johnson & Johnson
  • MedImmune LLC
  • Merck Serono GmbH
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Frequently Asked Questions about the Global Market for Systemic Lupus Erythematosus (Sle) Drugs

What is the estimated value of the Global Market for Systemic Lupus Erythematosus (Sle) Drugs?

The Global Market for Systemic Lupus Erythematosus (Sle) Drugs was estimated to be valued at $183.3 Million in 2020.

What is the growth rate of the Global Market for Systemic Lupus Erythematosus (Sle) Drugs?

The growth rate of the Global Market for Systemic Lupus Erythematosus (Sle) Drugs is 5.4%, with an estimated value of $264.5 Million by 2027.

What is the forecasted size of the Global Market for Systemic Lupus Erythematosus (Sle) Drugs?

The Global Market for Systemic Lupus Erythematosus (Sle) Drugs is estimated to be worth $264.5 Million by 2027.

Who are the key companies in the Global Market for Systemic Lupus Erythematosus (Sle) Drugs?

Key companies in the Global Market for Systemic Lupus Erythematosus (Sle) Drugs include Amgen, Inc., Bristol, Myers Squibb Company, GlaxoSmithKline PLC, Immunomedics, Inc., Johnson & Johnson, MedImmune LLC, Merck Serono GmbH and Teva Pharmaceutical Industries Ltd..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
  • Table 2: World Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • Table 3: World 15-Year Perspective for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027

III. MARKET ANALYSIS
  • UNITED STATES
  • Table 4: USA Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 5: USA Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • CANADA
  • Table 6: Canada Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 7: Canada Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • JAPAN
  • Table 8: Japan Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 9: Japan Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • CHINA
  • Table 10: China Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 11: China Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • EUROPE
  • Table 12: Europe Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
  • Table 13: Europe Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • Table 14: Europe 15-Year Perspective for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2018 & 2027
  • FRANCE
  • Table 15: France Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 16: France Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • GERMANY
  • Table 17: Germany Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 18: Germany Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • ITALY
  • Table 19: Italy Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 20: Italy Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • UNITED KINGDOM
  • Table 21: UK Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 22: UK Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • REST OF EUROPE
  • Table 23: Rest of Europe Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 24: Rest of Europe Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • ASIA-PACIFIC
  • Table 25: Asia-Pacific Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 26: Asia-Pacific Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
  • REST OF WORLD
  • Table 27: Rest of World Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
  • Table 28: Rest of World Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR

IV. COMPETITION
  • Total Companies Profiled: 43

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Immunomedics, Inc.
  • Johnson & Johnson
  • MedImmune LLC
  • Merck Serono GmbH
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA